Breaking News

Financial Report: Merck

April 29, 2014

Revenues down 4% in the quarter

1Q Revenues: $10.3 billion (-4%)

1Q Earnings: $1.7 billion (+7%)

Comments: Pharmaceutical sales were down 5% to $8.5 billion, including a 2% negative impact from foreign exchange, and loss of market exclusivity for products, including TEMODAR (-62%), NASONEX and SINGULAIR (-19% and 20%, respectively) and COZAAR (-23%). Combined sales of ZETIA and VYTORIN decreased 5% to $972 million, driven by lower demand in the U.S. Combined sales of REMICADE and SIMPONI were up 16% to $760 million in the quarter. ISENTRESS sales were up 8% to $390 million.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision